Cronos Group Inc. (NASDAQ:CRON) Stock Has Average Price Target of $2.30

Shares of Cronos Group Inc. (NASDAQ:CRON) have been given an average rating of “Buy” by the five brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $2.30.

A number of research firms have recently commented on CRON. Wall Street Zen raised shares of Cronos Group from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised shares of Cronos Group from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. TD Securities reiterated a “buy” rating on shares of Cronos Group in a research note on Monday, September 28th. Finally, Zacks Research upgraded shares of Cronos Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 22nd.

Cronos Group Stock Performance

CRON opened at $3.61 on Friday. The business has a 50 day moving average price of $3.31 and a 200 day moving average price of $2.88. Cronos Group has a twelve month low of $2.28 and a twelve month high of $3.91. The firm has a market cap of $1.32 billion, a P/E ratio of 21.24 and a beta of 0.96.

Cronos Group (NASDAQ:CRON) last announced its earnings results on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. Cronos Group had a return on equity of 2.56% and a net margin of 28.04%. The firm had revenue of $63.45 million during the quarter, compared to analysts’ expectations of $51.15 million. As a group, analysts anticipate that Cronos Group will post 0.12 earnings per share for the current fiscal year.

More Cronos Group News

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q3 net revenue rose 73% year over year on an organic, constant-currency basis, with the company reporting record net revenue, gross profit and adjusted EBITDA. Revenue of $63.45 million and earnings of $0.04 per share also exceeded analyst estimates of $51.15 million and $0.03, respectively. Cronos Group Reports 2026 Third Quarter Results
• Positive Sentiment: Growth was broad-based: Cronos posted record Canadian sales, a record quarter in Germany, and its 11th consecutive quarter of record net revenue in Israel. Its Spinach brand retained the top position in Canadian vapes and edibles, while the Canatolar acquisition expands its European reach. Q3 2026 Earnings Call Highlights
• Neutral Sentiment: The company said it reduced its share count, which can support per-share results, though the available reports do not quantify the effect. Cronos Group Reports 2026 Third Quarter Results
• Negative Sentiment: Despite beating estimates, Q3 earnings of $0.04 per share were below the $0.07 reported a year earlier. A separate valuation discussion also notes that the stock’s 93% three-year gain puts more focus on whether current earnings justify its valuation. Cronos Group Stock Looks Hard To Call Following Its 93% Run

Institutional Investors Weigh In On Cronos Group

A number of hedge funds have recently bought and sold shares of the company. Chicago Partners Investment Group LLC grew its position in shares of Cronos Group by 26.5% in the third quarter. Chicago Partners Investment Group LLC now owns 29,601 shares of the company’s stock valued at $99,000 after purchasing an additional 6,200 shares during the last quarter. State of Wyoming acquired a new position in shares of Cronos Group during the 3rd quarter worth about $468,000. Squarepoint Ops LLC lifted its position in shares of Cronos Group by 14.6% during the 2nd quarter. Squarepoint Ops LLC now owns 42,661 shares of the company’s stock worth $119,000 after purchasing an additional 5,441 shares during the last quarter. Spark Investment Management LLC acquired a new position in shares of Cronos Group during the 2nd quarter worth about $77,000. Finally, Amundi boosted its stake in Cronos Group by 14.8% during the 2nd quarter. Amundi now owns 24,728 shares of the company’s stock valued at $69,000 after purchasing an additional 3,180 shares during the period. 8.71% of the stock is currently owned by institutional investors.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company focused on developing, producing and commercializing cannabis and cannabis-derived consumer products. The company serves adult-use and medical cannabis markets through a portfolio of brands and sells products such as dried flower, pre-rolls, vaporizers, edibles, oils and other cannabis formats, subject to applicable regulations.

Its brand portfolio has included Spinach, which is positioned primarily in the adult-use cannabis market, as well as Lord Jones and PEACE NATURALS.